[18F]PI-2620作为阿尔茨海默病淀粉样蛋白/陶/神经变性分类通用生物标志物的效用:双相PET显像探索性研究
探索性研究纳入25例受试者(15例淀粉样蛋白阳性AD、10例淀粉样蛋白阴性健康对照),采用双相[18F]PI-2620 PET(早期相反映脑灌注、晚期相反映陶病理)及晚期相[18F]florbetaben PET和脑MRI,通过空间协方差分析识别AD相关模式;各模式表达评分可区分AD与健康对照(P < .0001),联合ADRP-tau与ADRP-perfusion评分预测淀粉样蛋白状态的判别准确率为96%,提示[18F]PI-2620可能作为A/T/N分类的单一生物标志物。
要点
- 双相[18F]PI-2620 PET可同时获取灌注(早期相)与陶病理(晚期相)信息,空间协方差分析识别出ADRP-amyloid、ADRP-tau和ADRP-perfusion三种模式。
- ADRP-tau与ADRP-perfusion评分联合预测淀粉样蛋白状态的判别准确率为96%。
- 各ADRP表达评分区分AD与健康对照的P < .0001,且评分间正相关并与多项临床疾病严重程度指标相关。
核心结论
- 对AD与正常对照的分析提示[18F]PI-2620可能作为A/T/N分类的单一生物标志物。
研究设计与样本
- 探索性研究,纳入25例受试者(15例男性、10例女性,平均年龄64.5 ± 10.1岁,范围51-89岁),包括15例淀粉样蛋白阳性AD和10例淀粉样蛋白阴性健康对照;采集双相[18F]PI-2620 PET(早期相反映脑灌注、晚期相反映陶病理)、晚期相[18F]florbetaben PET(反映淀粉样蛋白病理)及高分辨率脑MRI;以小脑灰质为参考区将PET图像转换为标准化摄取值比图,在标准脑空间采用公开领域成熟计算工具箱分别进行空间协方差分析。
关键影像表现/征象
- 识别出AD相关空间协方差模式(ADRP),涵盖脑淀粉样蛋白、陶和灌注的显著异常特征(分别为ADRP-amyloid、ADRP-tau和ADRP-perfusion);这些拓扑分布间存在一定重叠,尤以ADRP-tau与ADRP-amyloid之间明显。
诊断标准与关键数值
- 各ADRP模式表达评分可区分AD与健康对照(P < .0001);联合ADRP-tau与ADRP-perfusion评分进行组判别分析预测淀粉样蛋白状态的准确率为96%;各评分间正相关,并与合并受试者组中多项临床疾病严重程度指标正相关。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Our purpose was to identify spatial covariance patterns of dual-phase [18F]PI-2620 PET in biomarker-confirmed Alzheimer disease (AD) and healthy control subjects by applying data-driven multivariate analysis to multimodality neuroimaging data. We also tested the ability of pattern expression values in individual subjects to predict amyloid status and evaluate the efficacy of [18F]PI-2620 as a single, universal biomarker for the amyloid/tau/neurodegeneration (A/T/N) classification.
MATERIALS AND METHODS: Twenty-five subjects (15 men, 10 women, mean age: 64.5 ± 10.1, range 51-89) including 15 with amyloid-positive AD and 10 amyloid-negative healthy controls were analyzed. Brain PET images of dual-phase [18F]PI-2620 (early-phase for cerebral perfusion; late-phase for tau pathology) and late-phase [18F]florbetaben for amyloid pathology were acquired in each participant alongside high-resolution brain MRI. PET images were converted into maps of standard uptake value ratio by using cerebellar GM as reference region. Spatial covariance analysis was performed separately in the standard brain space by using a well-established computing toolbox in the public domain.
RESULTS: We identified distinct Alzheimer disease-related patterns (ADRP) of spatial covariance capturing prominent abnormal features in brain amyloid, tau, and perfusion (ADRP-amyloid, ADRP-tau, and ADRP-perfusion) underlying this disease. There was some overlap among these topographies particularly between ADRP-tau and ADRP-amyloid. ADRP expression scores of each pattern differentiated AD from healthy controls (P < .0001) with group discriminant analysis yielding an accuracy of 96% in predicting amyloid status with the combination of ADRP-tau and ADRP-perfusion scores. These scores correlated positively among themselves and with several clinical measures of disease severity in the combined subject group.
CONCLUSIONS: Analysis of AD and normal controls suggests a potential role of [18F]PI-2620 as a single biomarker for the A/T/N classification.
引用
- Franceschi AM, Peng S, Banegas JI, et al. Utility of [18F]PI-2620 as Universal Biomarker for the Amyloid/Tau/Neurodegeneration Classification of Alzheimer Disease: An Exploratory Study with Dual-Phase PET Imaging. AJNR Am J Neuroradiol. 2026. PMID: 41571406. doi:10.3174/ajnr.A8980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。